Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nurix reported fiscal Q3 2026 revenue of $673.1 million and net income of $549.8 million ($4.73 diluted EPS), driven by $653.2 million of one-time license revenue from the Roche collaboration. The company dosed the first patient in the registrational Phase 3 DAYBreak CLL-306 trial, which will compare bexobrutideg against pirtobrutinib in roughly 620 relapsed/refractory CLL/SLL patients. Phase 1a data presented at EHA 2026 showed an 83.0% objective response rate and 22.1-month median progression-free survival in heavily pretreated CLL patients.
Key figures
- Eps
- 4.73
- Revenue
- 673100000
- Revenue Yoy
- $673.1M vs $7.9M prior year (driven by one-time $653.2M Roche license revenue)
- Ga expense
- 34400000
- Net income
- 549800000
- Rd expense
- 79300000
- Cash runway
- second half of 2029
- Orr phase1a
- 83.0%
- Phase3 trial size
- approximately 620 patients
- Median pfs phase1a
- 22.1 months
- Cash and securities
- 1100000000
- Sanofi total earned
- $139 million
- Roche upfront received
- 700000000
- Sanofi future milestones
- $455 million
- Collaboration earnings quarter
- $27M from Gilead, Pfizer and Sanofi including $10M Sanofi STAT6 milestone
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.